Loading...
Market
Number of countries approving Tagrisso for Stage III EGFR-mutated lung cancer by end of 2024
5
Resolution / Starting Odds
Less than 20 • 33%
20 to 40 • 33%
More than 40 • 34%
Official government health agency websites, AstraZeneca press releases
Story
AstraZeneca's Tagrisso Shows 84% Reduction in Disease Progression in Trials
Jun 2, 2024, 01:30 PM
Tagrisso, one of AstraZeneca's drugs, greatly slowed cancer progression for patients with stage 3 lung cancer, particularly those with a specific genetic mutation, achieving a major PFS benefit (HR=0.16). The drug reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer compared to a placebo in the LAURA Phase III trial, with a median progression-free survival of several years. These results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
View original story
Similar markets
0 to 2 • 25%
3 to 5 • 25%
6 to 8 • 25%
More than 8 • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
1-5 countries • 33%
6-10 countries • 33%
More than 10 countries • 34%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0 countries • 20%
1-3 countries • 20%
4-6 countries • 20%
7-9 countries • 20%
10 or more countries • 20%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
1-5 countries • 33%
6-10 countries • 33%
More than 10 countries • 34%
Yes • 50%
No • 50%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%